

^STN;HighlightOn= ;
Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspal648rx1

DISCONNECT.

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

```
NEWS 1 JAN 02 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 16 CAS patent coverage enhanced to include exemplified
        nonpatent substances
NEWS 4 JAN 28 HSCAMENU, HSCAPP, and HSCATOLD enhanced with new
        custom TDC display formats
NEWS 5 JAN 28 MADDAM searching enhanced
NEWS 6 JAN 28 HSCENE now provides USPTO sequence data within 3 days
        of publication
NEWS 7 JAN 28 TWOWENTER enhanced with reloaded MENTINP segment
NEWS 8 JAN 28 MENTINP and TMENTINP reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 9.1, now available
NEWS 10 FEB 20 DPT now available as a replacement to DPCI
NEWS 11 FEB 26 IEDBE reloaded with enhancements
NEWS 12 FEB 26 IMCDDDDDDDD reloaded with enhancements
NEWS 13 FEB 26 WOTNTRY/WDTRY/WDTV enhanced with EPLA and current
        H.C. National Patent Classification
NEWS 14 MAR 11 IEDTDB, IEDTAB, and IPIUDB enhanced with new custom
        TDC display formats
NEWS 15 MAR 11 CAS REGISTRY enhanced with additional experimental
        results
NEWS 16 MAR 11 AN/CONLINE and CASREACT patent number format for U.S.
        applications updated
NEWS 17 MAR 11 IEDT now available as a replacement to IEDPT
NEWS 18 MAR 11 FMRACE, FMRBR, and FMRACE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 FEB 20 FEBRUARY 2008
        RECAPITULATORY OF CURRENT WINDOW VERSION IS V8.1
        AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008
```

```
NEWS 21 STN Operating Hours Blue Helm Desk Availability
NEWS 22 WELCOME Banner and News Items
NEWS 23 For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial processes or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

TOTAL
EFFECTIVE
0.21

```

16 ANSWER 1 OF 2 ***ADVICE CONDUCTING 2008 ACS ON STN
17 Method and ****peptide*** **aminoacids*** **phosphates***
18 amino acids ****peptides*** I diabetes mellitus in infants .2 composition
19 A ****nutritional*** commn for the prophylaxis of insulin-dependent
20 diabetes mellitus time 1 in infants The ****nutritional*** commn
21 making a peptide which has individual amino acids rich in active
22 ****peptides*** ****phosphates*** 2 The ****peptides*** rich in active
23 ****peptides*** ****phosphates*** favor the induction of tolerance to oral
24 amino acids in an infant susceptible to insulin-dependent diabetes mellitus
25 time 1
26 COPEN:PIXORZ , 14 pp.

```

Q0 DOT Int Annl, 14 pp.

ANNEPPE 2 DE 2 BIOLOGIE/NOUVEAUX (A) 2008 The American Corporation on STN
 food allergy, intolerance and prevention of atopic diseases
 About 2% of children in Europe suffer from cow's milk allergy, and 5%
 of the adult population suffer from food-induced clinical symptoms. Food
 allergy is often a disease of infancy and childhood. It can be simplified
 as a breakdown of oral tolerance or failure of its induction. Mucosal
 antigen exposure generally leads to 3 important immunoregulatory processes
 which are not entirely understood. These are immune exclusion, immune
 elimination, and immune regulation (oral tolerance), which can be defined
 as antigen-specific humoral or non-reactivity after prior mucosal
 (intestinal) exposure. The induction of oral tolerance is an active
 process which is finely tuned by the intestinal epithelium (including
 intraepithelial lymphocytes), specialized antigen-presenting cells, and
 lymphocytes of the lamina propria. Different immunological processes are
 induced depending on the nature of the antigen, frequency and dose of
 administration, and the age of the individual. Administration of "low"
 antigen doses is associated with induction of suppressor cells which
 secrete regulatory cytokines such as *****TGF*****, *****IL10*****, and
IL-4, **IL-5**, and others. **Th2** T-cell. However, antigen administration also
 leads to suppression of **Th1**, **Th2**, and cell-mediated immune responses
 which suggest a suppression of **Th1** and **Th2**-dependent mechanisms. Anergy,
 clonal deletion, and other forms of immune deviation can be a part of the
 suppression of systemic immunity after mucosal antigen exposure. **Th1** and
 cell-mediated immune responses are implicated in a majority of clinical
 symptoms. The skin, the gastrointestinal tract, and the lungs are most
 commonly affected with clinical features ranging from mild to severe
 generalized (at times fatal) anaphylactic reactions. The incidence of
 milk allergy, and other food-induced symptoms in infancy have led to the
 development of *****nutritions***** (nonhydrolytic formulas with
*****lactose***** and *****protein***** with different degrees of hydrolysis). A number of
 nonreactive randomized and placebo-controlled clinical feeding studies
 seem to indicate a reduction in the incidence of milk allergy and of
 allergic symptoms in infants of families with a positive atopic history
 (parent and/or sibling).
 Allergologie (***Nov 1997***) Vol. 20, No. 11, pp. 565-570. print.
 CODEN: ALLRDI. ISSN: 0344-5062.

-- eduardo?/au and schiffri?/au
 L7 0 EDUARDO?/AU AND SCHIFFRIN?/AU
 -- denis?/au and breuille?/au
 L8 21 DENIS?/AU AND BREUILLE?/AU
 -- (denis breuille)/au
 L9 0 (DENIS BREUILLE)/AU
 -- stephanie?/au and blum-sperisen?/au
 L10 0 STEPHANIE?/AU AND BLUM-SPERISEN?/AU
 -- anne?/au and donnet-hughes?/au
 L11 0 ANNE?/AU AND DONNET-HUGHES?/AU
 -- magali?/au and faure?/au
 L12 0 MAGALI?/AU AND FAURE?/AU
 -- claudia?/au and roessler?/au
 L13 0 CLAUDIA?/AU AND ROESSLE?/AU
 => marco?/au and turini?/au

L14 0 MARCO?/AU AND TURINI?/AU

L15 0 L6 AND L8

=> d his

(FILE 'HOME' ENTERED AT 02:08:42 ON 14 APR 2008)

T1 FILE 'IMMEDIATE BIOLOGIC, CAPLUS' ENTERED AT 02:09:15 ON 14 APR 2008
T2 150000 INFORMATION
T3 000000 TGF-B AND TGF-BETA
T4 014 T1 AND T2
T5 1 T3 AND /CASEIN AND WHEY)
T6 2 T4 AND 1070-2000/DV
T7 2 T5D BFM T5 (0 INDICATES REMOVED)
T8 0 BETA2/MI AND SCHIFFEN?/AU
T9 0 BETA2/MI AND SCHIFFEN?/AU
T10 0 BETA2/MI AND BILIM-CODESPN?/AU
T11 0 ANNE?/MI AND DOMNET-HUGHES?/AU
T12 0 MARCIT?/MI AND FAIRER?/MI
T13 0 CATAIT?/MI AND FOREST?/AU
T14 0 MARCO?/MI AND TURINI?/AU
T15 0 L6 AND L8

=> logoff
ALL 14 QUESTIONS AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF (V) IN/OUT/...

LOGOFF IN/OUT/...

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR CHARGING ACCOUNTS)

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 02:13:07 ON 14 APR 2008

STN/PR	FILE	TOTAL
ENTD	ENTD	ENTD
57.61	57.61	57.82
-0.80	-0.80	-0.80